H.R. 10476

Glaucoma Vision Act of 2026

34 cosponsors

Where it stands

Introduced Sep 16
Committee Now
House of Representatives —
Senate —
Law —

Introduced Sep 16
Committee Now
House of Representatives —
Senate —
Law —

Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Oversight and Government Reform, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (Sep 16)

Votes

No roll-call votes yet.

Official summary

No official summary yet.

Text of the bill

Expand all

Sec. 1. Short title

Sec. 2. Findings

Sec. 3. Requiring coverage of annual glaucoma screenings for certain individuals

Sec. 4. Glaucoma detection and prevention program

Sec. 5. Glaucoma and optic nerve damage research

Subpart 9 of part C of title IV of the Public Health Service Act (42 U.S.C. 285i et seq.) is amended by adding at the end the following:

Text this section adds to the law

456A. Grants for glaucoma and optic nerve damage research

(a) In general. The Director of the Institute shall award grants, on a competitive basis, for research related to glaucoma and optic nerve damage, including—

(1) optic nerve regeneration and repair;

(2) neuroprotection strategies to prevent retinal ganglion cell loss;

(3) gene therapies directed at glaucoma-related pathways; and

(4) stem cell-based therapies and other advanced approaches to preserving or restoring vision.

(b) Authorization of appropriations. There is authorized to be appropriated to carry out this section $10,000,000 for the period of fiscal years 2027 through 2028.